| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Letters to the Editor |
Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio
In Response:
We completely agree with Masojc et al. that "Trp149Stop is a mutation" yielding a dysfunctional product with a role in tumorigenesis. Moreover, their data reporting comparable frequency of ARLTS1 Trp149Stop variant in unselected ovarian cancers and controls agrees with our initial observations that the frequency of this variant is similar in patients with sporadic cancer and control cases (1).
We also proposed that down-regulation of ARLTS1 by deletion and/or hypermethylation is a frequent event in sporadic cancers, including ovarian cancers, and that this mechanism may represent the counterpart of ARLTS1 mutations observed with increased frequency in familial cancers (1, 2). In support of ARLTS1 involvement in familial cancer predisposition, a second variant (Cys148Arg) has been shown to confer increased risk for familial breast cancer (3).
In the light of two studies by Frank et al. linking Trp149Stop variant to increased risk of familial breast cancer in BRCA1-negative and BRCA2-negative families (4) and bilateral breast cancer (3), it would be interesting to determine the difference in Trp149Stop frequency between sporadic and familial ovarian tumors in various human populations.
References
Related Article
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |